Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received an average rating of “Hold” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $175.00.
Several equities research analysts have issued reports on NVAX shares. Cowen started coverage on Novavax in a report on Friday, January 21st. They set an “outperform” rating and a $150.00 price objective on the stock. Bank of America began coverage on Novavax in a report on Friday. They issued an “underperform” rating and a $35.00 price target for the company. StockNews.com began coverage on Novavax in a report on Thursday, March 31st. They issued a “hold” rating for the company. HC Wainwright lowered their price target on Novavax from $294.00 to $207.00 and set a “buy” rating for the company in a report on Thursday, March 3rd. Finally, B. Riley lowered their price target on Novavax from $203.00 to $181.00 in a report on Wednesday, May 11th.
NVAX stock traded down $5.22 during midday trading on Friday, hitting $53.21. 182,547 shares of the company’s stock were exchanged, compared to its average volume of 5,791,291. Novavax has a 12-month low of $41.33 and a 12-month high of $277.80. The firm has a 50 day moving average price of $62.05 and a 200-day moving average price of $108.65. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of -2.97 and a beta of 1.59.
In other news, Director James F. Young sold 12,500 shares of the company’s stock in a transaction on Thursday, March 31st. The stock was sold at an average price of $73.58, for a total value of $919,750.00. Following the completion of the sale, the director now owns 62,590 shares in the company, valued at $4,605,372.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in NVAX. Truist Financial Corp raised its position in shares of Novavax by 123.4% during the third quarter. Truist Financial Corp now owns 4,705 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 2,599 shares during the period. Principal Financial Group Inc. raised its position in Novavax by 89.5% during the third quarter. Principal Financial Group Inc. now owns 46,649 shares of the biopharmaceutical company’s stock valued at $9,671,000 after buying an additional 22,033 shares during the period. Alliancebernstein L.P. raised its position in Novavax by 3.6% during the third quarter. Alliancebernstein L.P. now owns 46,021 shares of the biopharmaceutical company’s stock valued at $9,541,000 after buying an additional 1,593 shares during the period. Rafferty Asset Management LLC raised its position in Novavax by 3.4% during the third quarter. Rafferty Asset Management LLC now owns 12,864 shares of the biopharmaceutical company’s stock valued at $2,667,000 after buying an additional 425 shares during the period. Finally, Allianz Asset Management GmbH raised its position in Novavax by 177.7% during the third quarter. Allianz Asset Management GmbH now owns 137,624 shares of the biopharmaceutical company’s stock valued at $28,532,000 after buying an additional 88,058 shares during the period. 43.91% of the stock is currently owned by institutional investors.
About Novavax (Get Rating)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.